Intravenous or Inhaled Pentamidine for Treating Pneumocystis carinii Pneumonia in AIDS
Authors:
- David ChernoffDCDavid Chernoff
- David W. FeigalDFDavid W. Feigal
- Pat JosephPJPat Joseph
- Charles McDonaldCMCharles McDonald
- Jeffrey A. GoldenJGJeffrey A. Golden
- 1 August 1990
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 113 (3) , 203-209
Abstract
To evaluate the efficacy and toxicity of aerosolized pentamidine and of reduced-dose intravenous pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Randomized open study with serial pulmonary function testing and measurement of pentamidine concentrations in plasma and bronchoalveolar lavage fluid. Of 44 men and 1 woman with a mild to moderate first episode of P. carinii pneumonia (Pao2 greater than or equal to 7.3 kPa [55 mm Hg]), 23 received aerosolized pentamidine and 22, intravenous pentamidine. Pentamidine isethionate, 600 mg by inhalation using a Respirgard II nebulizer (Marquest Medical Products, Inc., Englewood, Colorado) or 3 mg/kg body weight intravenously, administered once daily for 2 to 3 weeks. The planned 60-patient study was stopped after 45 patients had been enrolled. The rates (aerosolized compared with intravenous pentamidine) of initial failure, early recrudescence of symptoms, and relapse were 12% and 19% (difference, 7%; 99% confidence interval [CI], - 23% to 37%; P = 0.67), 35% and 0% (difference, 35%; CI, 13% to 58%; P = 0.02), and 24% and 0% (difference, 24%; CI, 4% to 49%; P = 0.03). The rates (aerosolized compared with intravenous pentamidine) of major toxicity were 0% (0 of 17 patients) and 10% (2 of 21 patients) (difference 10%; CI, -1% to 29%; P = 0.24). The mean (+/- SD) pentamidine concentration in bronchoalveolar lavage fluid for patients receiving aerosolized pentamidine was 96.6 +/- 65.1 ng/mL compared with 14.4 +/- 17.7 ng/mL for patients receiving intravenous treatment. Trough concentrations of pentamidine in plasma increased from 0 to 25.4 +/- 16.4, 56.5 +/- 26.1, and 61.1 +/- 56.0 ng/mL at the end of weeks 1, 2, and 3 of intravenous therapy, respectively. The data suggest that reduced-dose intravenous pentamidine was more effective than aerosolized pentamidine for treating mild to moderate P. carinii pneumonia. Systemic absorption during aerosolized therapy was minimal; daily doses of intravenous pentamidine resulted in increased accumulation of pentamidine in plasma.Keywords
This publication has 22 references indexed in Scilit:
- Inhaled Pentamidine and HypoglycemiaAnnals of Internal Medicine, 1988
- Inhaled or Reduced-Dose Intravenous Pentamidine for Pneumocystis carinii PneumoniaAnnals of Internal Medicine, 1987
- AEROSOLISED PENTAMIDINE AS SOLE THERAPY FOR PNEUMOCYSTIS CARINII PNEUMONIA IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROMEThe Lancet, 1987
- Use of a Specific and Sensitive Assay to Determine Pentamidine Pharmacokinetics in Patients with AIDSThe Journal of Infectious Diseases, 1986
- Dapsone-Trimethoprim for Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency SyndromeAnnals of Internal Medicine, 1986
- Trimethoprim-Sulfamethoxazole or Pentamidine for Pneumocystis carinii Pneumonia in the Acquired Immunodeficiency SyndromeAnnals of Internal Medicine, 1986
- Bronchoalveolar Lavage and Transbronchial Biopsy for the Diagnosis of Pulmonary Infections in the Acquired Immunodeficiency SyndromeAnnals of Internal Medicine, 1985
- A Screening Test for Airways ReactivityChest, 1982
- A Multiple Testing Procedure for Clinical TrialsBiometrics, 1979
- Group sequential methods in the design and analysis of clinical trialsBiometrika, 1977